Glenmark Pharmaceuticals Inc., USA launched Axitinib tablets in 1 mg and 5 mg strengths as an authorized generic version of Pfizer's Inlyta in the United States.
The targeted oral oncology medication is prescribed to treat advanced renal cell carcinoma, a common type of kidney cancer.
According to IQVIA data for the 12 months ended September 2026, Inlyta tablets generated approximately $538.4 million in annual US sales.
Glenmark Pharmaceuticals Inc, USA, on Monday announced the launch of Axitinib Tablets in 1 mg and 5 mg strengths, a generic version of Pfizer Inc's Inlyta tablets.
Glenmark Axitinib tablets (a generic equivalent to Pfizer's Inlyta) are used to treat advanced renal cell carcinoma (RCC), a type of kidney cancer.
"The launch of Axitinib tablets reinforces Glenmark's commitment to expanding access to quality, affordable medicines for patients in the United States," said Marc Kikuchi, President & Business Head, North America.
By adding this product to its portfolio, the company continues to strengthen focus on addressing the evolving needs of patients and healthcare providers, he said .
According to IQVIA sales data for the 12-month period ended September 2026, annual sales of Inlyta tablets in the US were around USD 538.4 million, the company said in a statement.



